European regulators approve Fractyl Health's first GLP-1 gene therapy clinical trial
European regulators have given the green light for Fractyl Health, a biotech near Boston, to begin its first human study of a GLP-1 gene therapy.
The therapy aims to provide a one-time treatment that could replace the daily GLP-1 injections and oral medications currently used for weight management and diabetes.
The approval follows a broader industry push to develop gene-based approaches that deliver sustained GLP-1 expression, potentially simplifying patient care.
Fractyl Health's CEO Harith Rajagopalan said the clearance marks a major milestone and the company will now enroll participants in the European trial.
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “European regulators greenlight Fractyl Health's clinical test of GLP-1 gene therapy”
read at Endpoints ↗
comments(0)
5-min edit window · permanent after that